Drug Type Nanobody, TriTAC |
Synonyms- |
Action modulators |
Mechanism CD3 modulators(T cell surface glycoprotein CD3 modulators), FLT3 modulators(Tyrosine-protein kinase receptor FLT3 modulators), Peptide hydrolase modulators(Peptide hydrolase modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | United States | 02 Sep 2022 |